0001062993-20-002296.txt : 20200513 0001062993-20-002296.hdr.sgml : 20200513 20200513070427 ACCESSION NUMBER: 0001062993-20-002296 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20200513 FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Trillium Therapeutics Inc. CENTRAL INDEX KEY: 0001616212 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36596 FILM NUMBER: 20871006 BUSINESS ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 BUSINESS PHONE: (416) 595-0627 MAIL ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 6-K 1 form6k.htm FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2020

Commission File Number: 001-36596

___________________

TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)

2488 Dunwin Drive
Mississauga, Ontario L5L 1J9
Canada
(Address of principal executive offices)
___________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [   ]      Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[   ]

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  Trillium Therapeutics Inc.
   
   
Date: May 13, 2020
  By:     /s/ James Parsons                                       
  Name: James Parsons
  Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit Description
  
99.1   News Release dated May 13, 2020

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Trillium Therapeutics Inc.: Exhibit 99.1 - Filed by newsfilecorp.com

FOR IMMEDIATE RELEASE NASDAQ: TRIL
  TSX: TRIL

 

TRILLIUM THERAPEUTICS TO PRESENT DATA ON CD47 BLOCKER
TTI-622 IN ADVANCED RELAPSED OR REFRACTORY LYMPHOMA AT THE
ASCO20 VIRTUAL SCIENTIFIC PROGRAM

CAMBRIDGE, MA, May 13, 2020 - Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at the Developmental Therapeutics Session of the ASCO20 Virtual Scientific Program to be held May 29-31, 2020. The presentation will highlight a first-in-human study evaluating TTI-622 in patients with advanced relapsed or refractory lymphoma.

Presentation details are as follows:

Presenter: Krish Patel, MD

Title: Ongoing, First-in-human, Phase 1 Dose Escalation Study of the Investigational CD47-blocker TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma

Session: Developmental Therapeutics - Immunotherapy

Abstract: 3030

Session Type: Poster Presentation (Poster #94)

The poster will be available on the meeting website beginning Friday, May 29 at 8:00 am ET. A copy of the poster will also be available on the Events and Presentations page of Trillium's website.

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system.

For more information visit: www.trilliumtherapeutics.com

Company Contact:

James Parsons

Chief Financial Officer

Trillium Therapeutics Inc.

416-595-0627 x232

james@trilliumtherapeutics.com

www.trilliumtherapeutics.com 

Media Relations:

Mike Beyer
Sam Brown Inc.

312-961-2502

mikebeyer@sambrown.com

-2-

 GRAPHIC 3 exhibit99-1x001.jpg GRAPHIC begin 644 exhibit99-1x001.jpg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end